biostudies-literatureGerber DENational Cancer Institute Midcareer Investigator Award in Patient-Oriented ResearchNational Cancer InstituteNCI NIH HHS44-49https://www.ebi.ac.uk/biostudies/studies/S-EPMC5836800biostudies-literatureUnknown117BACKGROUND:KRAS mutations are identified in approximately 25% of non-small cell lung cancer (NSCLC) cases and are associated with resistance to currently available targeted therapies. The MET oncogene may be implicated in malignant progression of KRAS-mutant tumors. In a pre-specified subset analysis of KRAS mutant cancers in an earlier phase 2 study of erlotinib plus the oral MET inhibitor tivantinib, combination therapy was associated with substantial clinical benefit compared to erlotinib alone (progression-free survival [PFS] HR 0.18; P < 0.01). The current study was conducted to evaluate this combination further in KRAS mutant non-small cell lung cancer (NSCLC). MATERIALS AND METHODS:Previously treated patients with advanced KRAS mutant NSCLC were randomized to receive either oral tivLung cancer (Amsterdam, Netherlands)Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer.PMC5836800K24 CA201543K24CA201543-011R2C2CA148394-010Socinski MAHuang CJohnson MLNeal JWHesketh PJBrahmer JRSchiller JHChai FBastos BRSubramaniam DSRosovsky RPWakelee HAKazakin JGerber DELilenbaum RCSchwartz BSequist LVDietrich MFShirai KKelly RJWang YfalseRandomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer.BACKGROUND:KRAS mutations are identified in approximately 25% of non-small cell lung cancer (NSCLC) cases and are associated with resistance to currently available targeted therapies. The MET oncogene may be implicated in malignant progression of KRAS-mutant tumors. In a pre-specified subset analysis of KRAS mutant cancers in an earlier phase 2 study of erlotinib plus the oral MET inhibitor tivantinib, combination therapy was associated with substantial clinical benefit compared to erlotinib alone (progression-free survival [PFS] HR 0.18; P < 0.01). The current study was conducted to evaluate this combination further in KRAS mutant non-small cell lung cancer (NSCLC). MATERIALS AND METHODS:Previously treated patients with advanced KRAS mutant NSCLC were randomized to receive either oral tiv2018-01-01T00:00:00Z2018 Mar2025-06-01T03:55:15.546Z2019-06-06T19:04:04ZS-EPMC58368002949625510.1016/j.lungcan.2018.01.010